These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 18388845)

  • 1. Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants.
    Lamont EB; Herndon JE; Weeks JC; Henderson IC; Lilenbaum R; Schilsky RL; Christakis NA;
    Med Care; 2008 Mar; 46(3):303-8. PubMed ID: 18388845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants.
    Lamont EB; Herndon JE; Weeks JC; Henderson IC; Lilenbaum R; Schilsky RL; Christakis NA
    J Natl Cancer Inst; 2005 Jul; 97(14):1080-3. PubMed ID: 16030306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitivity of Medicare claims data for measuring use of standard multiagent chemotherapy regimens.
    Lamont EB; Lan L
    Med Care; 2014 Mar; 52(3):e15-20. PubMed ID: 22410411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344).
    Lamont EB; Herndon JE; Weeks JC; Henderson IC; Earle CC; Schilsky RL; Christakis NA;
    J Natl Cancer Inst; 2006 Sep; 98(18):1335-8. PubMed ID: 16985253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hospital-based health care use correlates with incidence of adverse events among elderly Medicare patients treated in adjuvant chemotherapy trials (Alliance 70802).
    Lamont EB; Yu M; He Y; Saltz L; Muss H; Zaslavsky AM;
    J Geriatr Oncol; 2014 Jul; 5(3):230-7. PubMed ID: 24594119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience.
    Muss HB; Berry DA; Cirrincione C; Budman DR; Henderson IC; Citron ML; Norton L; Winer EP; Hudis CA;
    J Clin Oncol; 2007 Aug; 25(24):3699-704. PubMed ID: 17704418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expanding Beyond Maximum Grade: Chemotherapy Toxicity over Time by Age and Performance Status in Advanced Non-Small Cell Lung Cancer in CALGB 9730 (Alliance A151729).
    Wong ML; Gao J; Thanarajasingam G; Sloan JA; Dueck AC; Novotny PJ; Jatoi A; Hurria A; Walter LC; Miaskowski C; Cohen HJ; Wood WA; Feliciano JL; Stinchcombe TE; Wang X
    Oncologist; 2021 Mar; 26(3):e435-e444. PubMed ID: 32951293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.
    Strauss GM; Herndon JE; Maddaus MA; Johnstone DW; Johnson EA; Harpole DH; Gillenwater HH; Watson DM; Sugarbaker DJ; Schilsky RL; Vokes EE; Green MR
    J Clin Oncol; 2008 Nov; 26(31):5043-51. PubMed ID: 18809614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials.
    Di Maio M; Gallo C; Leighl NB; Piccirillo MC; Daniele G; Nuzzo F; Gridelli C; Gebbia V; Ciardiello F; De Placido S; Ceribelli A; Favaretto AG; de Matteis A; Feld R; Butts C; Bryce J; Signoriello S; Morabito A; Rocco G; Perrone F
    J Clin Oncol; 2015 Mar; 33(8):910-5. PubMed ID: 25624439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel.
    Liu MC; Demetri GD; Berry DA; Norton L; Broadwater G; Robert NJ; Duggan D; Hayes DF; Henderson IC; Lyss A; Hopkins J; Kaufman PA; Marcom PK; Younger J; Lin N; Tkaczuk K; Winer EP; Hudis CA;
    Cancer Treat Rev; 2008 May; 34(3):223-30. PubMed ID: 18234424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construct validity of medicare chemotherapy claims: the case of 5FU.
    Lamont EB; Lauderdale DS; Schilsky RL; Christakis NA
    Med Care; 2002 Mar; 40(3):201-11. PubMed ID: 11880793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel.
    Hensing TA; Peterman AH; Schell MJ; Lee JH; Socinski MA
    Cancer; 2003 Aug; 98(4):779-88. PubMed ID: 12910523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term Impact of CALGB 9343 on Radiation Utilization.
    Squeo G; Malpass JK; Meneveau M; Balkrishnan R; Desai RP; Lattimore C; Anderson RT; Showalter SL
    J Surg Res; 2020 Dec; 256():577-583. PubMed ID: 32805580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicity profile of Doxorubicin-Cyclophosphamide and Doxorubicin-Cyclophosphamide followed by Paclitaxel regimen and its associated factors among women with breast cancer in Ethiopia: A prospective cohort study.
    Gadisa DA; Assefa M; Wang SH; Yimer G
    J Oncol Pharm Pract; 2020 Dec; 26(8):1912-1920. PubMed ID: 32122234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy-associated toxicity in a large cohort of elderly patients with non-small cell lung cancer.
    Hardy D; Cormier JN; Xing Y; Liu CC; Xia R; Du XL
    J Thorac Oncol; 2010 Jan; 5(1):90-8. PubMed ID: 19884853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic burden of selected adverse events in patients aged ≥65 years with metastatic renal cell carcinoma.
    Hagiwara M; Hackshaw MD; Oster G
    J Med Econ; 2013 Nov; 16(11):1300-6. PubMed ID: 24004437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer.
    Kehl KL; Greenwald S; Chamoun NG; Manberg PJ; Schrag D
    JAMA Netw Open; 2021 May; 4(5):e2111113. PubMed ID: 34019086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of a Medicare Claims-based Algorithm for Identifying Breast Cancers Detected at Screening Mammography.
    Fenton JJ; Onega T; Zhu W; Balch S; Smith-Bindman R; Henderson L; Sprague BL; Kerlikowske K; Hubbard RA
    Med Care; 2016 Mar; 54(3):e15-22. PubMed ID: 23929404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validity of claims-based stroke algorithms in contemporary Medicare data: reasons for geographic and racial differences in stroke (REGARDS) study linked with medicare claims.
    Kumamaru H; Judd SE; Curtis JR; Ramachandran R; Hardy NC; Rhodes JD; Safford MM; Kissela BM; Howard G; Jalbert JJ; Brott TG; Setoguchi S
    Circ Cardiovasc Qual Outcomes; 2014 Jul; 7(4):611-9. PubMed ID: 24963021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel and doxorubicin, a highly active combination in the treatment of metastatic breast cancer.
    Dombernowsky P; Gehl J; Boesgaard M; Jensen TP; Jensen BV
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):13-8. PubMed ID: 8629030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.